Aditx Therapeutics

General Information
Business:

 

We are a preclinical stage life sciences company with a mission to prolong life and enhance life quality of patients that have undergone organ transplants. The discovery of immunosuppressive (anti-rejection) drugs over 40 years ago has made possible life-saving organ transplantation procedures. While these drugs prevent or delay organ rejection, transplanted organs often ultimately fail, and about 40% of transplanted organs survive no more than 5 years. Furthermore, immune suppression leads to significant undesirable side effects, such as increased susceptibility to life-threatening infections and cancers, because it is not specifically targeted towards the transplanted organs; rather, it indiscriminately and broadly suppresses immune function throughout the body.

 

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 2
Founded: 2017
Contact Information
Address 11161 Anderson Street, Suite 105-10014, Loma Linda, CA 92354, US
Phone Number (909) 488-0844
Web Address http://www.aditxt.com
View Prospectus: Aditx Therapeutics
Financial Information
Market Cap $53.3mil
Revenues $0 mil (last 12 months)
Net Income $-4.8 mil (last 12 months)
IPO Profile
Symbol ADTX
Exchange NASDAQ
Shares (millions): 1.9
Price range $5.50 - $5.50
Est. $ Volume $10.5 mil
Manager / Joint Managers Dawson James Securities
CO-Managers Network 1 Securities
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change